Total Payments
$39,183
2024 Payments
$22,549
Companies
9
Transactions
76
Medicare Patients
9,505
Medicare Billing
$378,386
Payment Breakdown by Category
Research$28,628 (73.1%)
Travel$8,381 (21.4%)
Food & Beverage$2,141 (5.5%)
Education$32.27 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $28,628 | 17 | 73.1% |
| Travel and Lodging | $8,381 | 29 | 21.4% |
| Food and Beverage | $2,141 | 29 | 5.5% |
| Education | $32.27 | 1 | 0.1% |
Payments by Type
Research
$28,628
17 transactions
General
$10,555
59 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $27,212 | 29 | $0 (2024) |
| Novo Nordisk AS | $4,950 | 12 | $0 (2019) |
| SANOFI US SERVICES INC. | $3,860 | 8 | $0 (2019) |
| ModernaTX, Inc. | $2,921 | 15 | $0 (2024) |
| Abbott Laboratories | $65.41 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $56.45 | 3 | $0 (2024) |
| ABBVIE INC. | $53.87 | 3 | $0 (2024) |
| Novo Nordisk Inc | $49.94 | 2 | $0 (2024) |
| Amgen Inc. | $14.42 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,549 | 49 | Eli Lilly and Company ($19,444) |
| 2023 | $3,659 | 3 | Eli Lilly and Company ($3,635) |
| 2019 | $3,735 | 8 | SANOFI US SERVICES INC. ($1,930) |
| 2018 | $6,160 | 10 | Eli Lilly and Company ($2,850) |
| 2017 | $3,080 | 6 | Novo Nordisk AS ($1,764) |
All Payment Transactions
76 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: Diabetes Care | ||||||
| 11/26/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,193.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 10/17/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: NEUROSCIENCE | ||||||
| 09/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $4,928.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,070.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,810.00 | Research |
| Study: A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | ||||||
| 09/06/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: Diabetes Care | ||||||
| 08/29/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: NEUROSCIENCE | ||||||
| 08/21/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $53.11 | General |
| 08/18/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $268.40 | General |
| 08/18/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $258.40 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $339.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $320.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $175.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $118.73 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $51.79 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $51.01 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $42.98 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $32.96 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $32.96 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $32.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $17.50 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $15.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $14.12 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $14.12 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $9,729 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $4,928 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $3,193 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE THE EVOLVE-1 STUDY | Eli Lilly and Company | $2,850 | 2 |
| A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly and Company | $2,786 | 2 |
| A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Dia | SANOFI US SERVICES INC. | $1,930 | 4 |
| A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia | SANOFI US SERVICES INC. | $1,930 | 4 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $1,283 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 38 | 2,314 | 2,915 | $224,486 | $97,454 |
| 2022 | 42 | 2,362 | 4,162 | $243,432 | $97,058 |
| 2021 | 36 | 2,096 | 2,622 | $214,601 | $87,227 |
| 2020 | 45 | 2,733 | 3,547 | $264,137 | $96,647 |
Total Patients
9,505
Total Services
13,246
Medicare Billing
$378,386
Procedure Codes
161
All Medicare Procedures & Services
161 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 203 | 203 | $47,096 | $25,913 | 55.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 148 | 258 | $54,954 | $23,362 | 42.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 104 | 142 | $20,448 | $8,461 | 41.4% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 16 | 19 | $8,740 | $4,143 | 47.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 248 | 415 | $5,188 | $3,486 | 67.2% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 12 | 12 | $5,568 | $3,380 | 60.7% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 19 | 21 | $6,825 | $3,380 | 49.5% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 179 | 198 | $10,890 | $3,259 | 29.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 36 | 36 | $3,780 | $2,729 | 72.2% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 183 | 198 | $6,930 | $2,598 | 37.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 205 | 243 | $13,365 | $2,515 | 18.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 200 | 254 | $6,096 | $1,933 | 31.7% |
| 82306 | Vitamin d-3 level | Office | 2023 | 42 | 49 | $3,626 | $1,421 | 39.2% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 84 | 138 | $3,450 | $1,314 | 38.1% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 60 | 60 | $3,600 | $1,135 | 31.5% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 70 | 76 | $3,192 | $1,123 | 35.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 36 | 36 | $1,476 | $1,098 | 74.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 19 | 24 | $3,120 | $946.22 | 30.3% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 17 | 19 | $2,185 | $768.55 | 35.2% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 34 | 51 | $2,040 | $681.36 | 33.4% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 37 | 44 | $1,100 | $388.96 | 35.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 12 | 12 | $492.00 | $366.12 | 74.4% |
| 82746 | Folic acid level, serum | Office | 2023 | 25 | 25 | $950.00 | $360.25 | 37.9% |
| 84154 | Psa (prostate specific antigen) measurement, free | Office | 2023 | 14 | 19 | $1,140 | $342.38 | 30.0% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 45 | 52 | $1,248 | $294.32 | 23.6% |
About Dr. Kevin Pounds, MD
Dr. Kevin Pounds, MD is a Family Medicine healthcare provider based in Tucson, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831138569.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Pounds, MD has received a total of $39,183 in payments from pharmaceutical and medical device companies, with $22,549 received in 2024. These payments were reported across 76 transactions from 9 companies. The most common payment nature is "" ($28,628).
As a Medicare-enrolled provider, Pounds has provided services to 9,505 Medicare beneficiaries, totaling 13,246 services with total Medicare billing of $378,386. Data is available for 4 years (2020–2023), covering 161 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Tucson, AZ
- Active Since 06/06/2006
- Last Updated 02/14/2012
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1831138569
Products in Payments
- EFPEGLENATIDE (Drug) $1,930
- SAR439977 (Drug) $1,930
- Victoza (Drug) $1,764
- Tresiba (Drug) $1,413
- FREESTYLE LIBRE 3 (Device) $41.08
- AIRSUPRA (Drug) $38.90
- UBRELVY (Drug) $36.25
- FREESTYLE LIBRE 2 (Device) $24.33
- Ozempic (Drug) $17.67
- VRAYLAR (Drug) $17.62
- FARXIGA (Drug) $17.55
- Otezla (Drug) $14.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Tucson
Laurence Marsteller, M.d, M.D
Family Medicine — Payments: $250,058
Family Medicine $250,058
Mrs. Dena Petersen, Md, MD
Family Medicine — Payments: $199,328
Family Medicine $199,328
Mrs. Katherine Wilson, Do, DO
Family Medicine — Payments: $50,937
Family Medicine $50,937
Dr. Kimy Charani, D.o, D.O
Family Medicine — Payments: $26,955
Family Medicine $26,955
Michael Bischof, D.o, D.O
Family Medicine — Payments: $22,995
Family Medicine $22,995
Dr. Netley Dsouza, Md, MD
Family Medicine — Payments: $15,850
Family Medicine $15,850